A high-throughput microfluidic nanoimmunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultralow-volume blood samples.
Antibodies, Viral
/ blood
COVID-19
/ blood
COVID-19 Serological Testing
/ economics
Dried Blood Spot Testing
High-Throughput Screening Assays
/ economics
Humans
Immunoassay
/ economics
Immunoglobulin G
/ blood
Microfluidic Analytical Techniques
/ economics
Reproducibility of Results
SARS-CoV-2
/ immunology
Sensitivity and Specificity
Specimen Handling
SARS-CoV-2
high-throughput serology
microfluidics
nanoimmunoassay
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
04 05 2021
04 05 2021
Historique:
entrez:
4
5
2021
pubmed:
5
5
2021
medline:
19
5
2021
Statut:
ppublish
Résumé
Novel technologies are needed to facilitate large-scale detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies in human blood samples. Such technologies are essential to support seroprevalence studies and vaccine clinical trials, and to monitor quality and duration of immunity. We developed a microfluidic nanoimmunoassay (NIA) for the detection of anti-SARS-CoV-2 IgG antibodies in 1,024 samples per device. The method achieved a specificity of 100% and a sensitivity of 98% based on the analysis of 289 human serum samples. To eliminate the need for venipuncture, we developed low-cost, ultralow-volume whole blood sampling methods based on two commercial devices and repurposed a blood glucose test strip. The glucose test strip permits the collection, shipment, and analysis of 0.6 μL of whole blood easily obtainable from a simple finger prick. The NIA platform achieves high throughput, high sensitivity, and specificity based on the analysis of 289 human serum samples, and negligible reagent consumption. We furthermore demonstrate the possibility to combine NIA with decentralized and simple approaches to blood sample collection. We expect this technology to be applicable to current and future SARS-CoV-2 related serological studies and to protein biomarker analysis in general.
Identifiants
pubmed: 33945500
pii: 2025289118
doi: 10.1073/pnas.2025289118
pmc: PMC8106336
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Research Council
Pays : International
Informations de copyright
Copyright © 2021 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Integr Biol (Camb). 2013 Apr;5(4):650-8
pubmed: 23443913
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
J Lab Autom. 2016 Jun;21(3):356-67
pubmed: 25805850
J Clin Med. 2020 Jul 24;9(8):
pubmed: 32722191
Nat Biotechnol. 2010 Sep;28(9):970-5
pubmed: 20802496
ACS Nano. 2016 Jan 26;10(1):1699-710
pubmed: 26741022
Nat Biotechnol. 2020 Oct;38(10):1174-1183
pubmed: 32855547
Clin Microbiol Infect. 2020 Oct;26(10):1386-1394
pubmed: 32603801
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16540-5
pubmed: 23012409
Lancet Infect Dis. 2021 Apr;21(4):e69-e70
pubmed: 32679085
Lab Chip. 2014 Aug 7;14(15):2642-50
pubmed: 24345965
Science. 2007 Jan 12;315(5809):233-7
pubmed: 17218526
Drug Test Anal. 2020 Jul;12(7):994-997
pubmed: 32386354
Science. 2020 Jun 5;368(6495):1060-1061
pubmed: 32414781
Nat Biomed Eng. 2020 Dec;4(12):1180-1187
pubmed: 32948854
Clin Microbiol Infect. 2019 Jul;25(7):907.e7-907.e12
pubmed: 30391583
Science. 2002 Oct 18;298(5593):580-4
pubmed: 12351675
Chem Commun (Camb). 2013 Feb 14;49(13):1264-6
pubmed: 23183795
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347